Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Skin Cancer, Melanoma
Kinnate Biopharma Inc (NASDAQ: KNTE)

Organization & Developments: Kinnate Biopharma

Parents

*Advancing compounds to target BRAF mutations, which come in three flavors: Class I, Class II, and Class III. Drugs exist to target Class I mutations, but not for the latter two type
2023: Kinnate Biopharma: Righting The Ship, But Still Not The Right Time (Rating Upgrade)_ seekingalpha.com
2023: Kinnate lays off 70% of employees, shaves pipeline to focus on CDK4 and pan-RAF inhibitor
2023: Novel Approach To BRAF Class II And III, But Uninspiring Data (NASDAQ:KNTE)